Fairmount Funds Management LLC - 10 Jun 2025 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Reporting relationship: Director
Issuer ticker: ZBIO
Reported as of: 10 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2025, 16:34:14 UTC
Prior SEC filing: 11 Jun 2025
Next SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 12 Jun 2025.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2025, 16:34.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (4)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: By: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Signature date: 12 Jun 2025

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: By: /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II LP
Signature date: 12 Jun 2025

CIK 0001830177

Kiselak Tomas

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: By: /s/ Tomas Kiselak
Signature date: 12 Jun 2025

CIK 0001663607

Harwin Peter Evan

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: By: /s/ Peter Harwin
Signature date: 12 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +18,500
Change %
Price: $0.000000
Shares after: 18,500
Date: 10 Jun 2025
Ownership: By Tomas Kiselak
Underlying class: Common Stock
Underlying amount: 18,500
Exercise price: $11.94
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service.

Footnote F2

Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC ("Fairmount" and each such investment vehicle, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC remarks

Fairmount and Fairmount Healthcare Fund II L.P. may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.